AEMD Explodes 471% on North Immunology Reverse Merger

Aethlon Medical shares surge 471% after agreeing to an all-stock reverse merger that takes stealth biotech North Immunology public, backed by a $180 million oversubscribed private placement to advance NOR-101.

Lead

What Is NOR-101 and Why Has It Ignited Such a Market Reaction?

NOR-101 is the asset at the center of the deal: a half-life extended bispecific antibody designed to simultaneously block IL-13 and IL-18, two cytokines that drive distinct but overlapping inflammatory cascades in atopic dermatitis. The dual-pathway mechanism distinguishes it from current market leaders that address only type 2 inflammation. By co-targeting IL-18 -- a driver of non-type 2 inflammation -- alongside IL-13, North Immunology is positioning NOR-101 as a potential treatment for the broader and harder-to-treat atopic dermatitis patient population, including those who respond poorly to existing biologic therapies. A Phase 1a study is expected to begin in the first quarter of 2027, with interim pharmacokinetic and safety data anticipated by mid-2027. Phase 1b and Phase 2b studies in atopic dermatitis are slated to initiate in 2027, with topline data from both expected in 2028.

How Does the Reverse Merger Structure Work?

Under the terms of the all-stock transaction, Aethlon will execute the merger through two wholly owned subsidiaries -- Nighthawk Merger Sub Corp. and Nighthawk Second Merger Sub, LLC. Existing Aethlon stockholders are expected to retain approximately 4.75% of the combined company at close, while North Immunology stockholders, including participants in the concurrent private placement, are expected to hold the remaining 95.25%. The asymmetric ownership split reflects the economic reality of a reverse merger used primarily as a regulatory and listing mechanism: the surge in AEMD shares represents the market pricing a small stub position against a substantially larger private-company valuation. Both boards have approved the transaction, which remains subject to customary regulatory and shareholder conditions.

The Hedge Fund Origins Behind North Immunology

North Immunology spent approximately two years incubating inside a biotech-focused hedge fund before emerging as an independent company for this transaction. That structure allowed the team to develop NOR-101's scientific rationale and early data package in a capital-efficient environment before seeking public markets access. The $180 million private placement -- described as oversubscribed -- attracted a consortium of institutional healthcare investors including Bain Capital Life Sciences, Janus Henderson Investors, Deep Track Capital, Longitude Capital, Soleus Capital, Invus, Sirenia Capital Management, Farallon Capital Management, Adage Capital Partners, and TCGX, signaling strong institutional conviction in the program ahead of any Phase 1 human data.

Outlook

With the combined company's capital runway extending into the second half of 2028, North Immunology has sufficient funding to reach meaningful clinical inflection points for NOR-101 before needing to return to markets. The first Phase 1 human data mid-2027 will be the next material catalyst. The atopic dermatitis market has drawn intense competitive interest from both large pharmaceutical companies and emerging biotechs, and a differentiated bispecific antibody mechanism addresses an unmet need in patients with inadequate responses to current biologics. Execution of the merger close and initiation of Phase 1a are the immediate milestones investors will track through the first quarter of 2027.

Mentioned tickers: AEMD, NRTX